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1. Introduction 
The Reactive Oxygen Species (ROS) and the Reactive Nitrogen Species (RNS) are highly 
reactive molecules participating as mediators in biological processes such as metabolic cellular 
respiration, neurotransmission, translation and transcription gene, and  inflammatory-type 
reactions among others (D. Almaguer & L.E. Almaguer,  2006; Boots et al., 2008; Uttara, 
2009). Additionally, these molecules have the capacity to interact with nucleophilic centers 
of biomolecules by modulating their activity or by irreversibly modifying them in order to 
generate different kind of radicals (D. Almaguer & L.E. Almaguer,  2006). 
The main oxygen radicals are the hydroxyl (-OH), the superoxide anion (O2-), and the 
hydrogen peroxide (H2O2), while the main nitrogen radical is the nitric oxide (NO), but 
also, it is known that the ROS can interact with -NO generating new species with high 
oxidizing power (Martinez et al., 2010).  In aerobic systems most of the ROS come from the 
mitochondrial oxidative metabolism, where 1-2% of the oxygen is converted into free 
radicals (Uttara et al., 2009). Other less important sources of ROS are the autoxidation of 
catecholamines and hemoproteins that occurs in the cytoplasm, nuclear membrane, 
endoplasmic reticulum and peroxisomes (Boots et al., 2008; Martínez et al, 2010). The 
concentration of ROS or RNS in organisms is determined by the balance between the rate of 
production of reactive species and the elimination rate of these compounds by the action of 
enzymes and antioxidants (AO) (Dorado et al., 2003). Thus, under conditions of 
physiological homeostasis, a balance exists between the cellular processes that contribute to 
the production of ROS / RNS, and those factors such as superoxide dismutase (SOD), 
catalase (Cat) and glutathione peroxidase (GPx), which contribute to their elimination 
(Dorado et al., 2003; Martínez et al., 2010). Thus, alterations in the balance between these 
systems, pro-oxidants and antioxidants can lead to intracellular accumulation of free 
radicals (FR), causing oxidative stress states (Dorado et al., 2003; Kelsey, et al , 2010; Uttara, 
2009). 
Specifically, oxidative stress and redox imbalance is the combined result of excessive 
formation of oxidant species (ROS/RNS) and/or a decreasing in the efficiency of 
endogenous antioxidant systems. Thus, the combination of these factors converge in 
damaging to biomolecules such as DNA, RNA, proteins, carbohydrates and lipids. This 
probably initiate processes of mitochondrial dysfunction and excitotoxicity (Kelsey, et al., 
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2010; Dorado et al., 2003), which in turn results in structural and functional alterations of 
organic macromolecules, leading the affected cells to degenerative processes and cell death 
by necrosis or apoptosis (D. Almaguer & L.E. Almaguer,  2006; Gonzalez et al. 1999; 
Martinez et al., 2010). The deleterious effects of ROS on cell integrity, eventually may drive 
or participate in the development of diseases or pathological processes such as 
atherosclerosis, cancer, diabetes, rheumatoid arthritis, ischemia-reperfusion syndrome, 
cardiovascular disease, chronic inflammatory processes, shock Blackwater and other 
degenerative diseases in humans and animals (Freidovich, 1999; Fang et al., 2002). However, 
is hard to establish whether these reactive species represent a primary etiologic factor or 
product from the damaged tissue (Gonzalez et al., 1999). 
The biochemical composition of the brain tissue makes it especially susceptible to the action 
of ROS/RNS, as it contains a pool of unsaturated lipids which are suitable to oxidative 
modification and lipid peroxidation. The double chains of unsaturated fatty acids are 
targeted for attack by free radicals, which initiate a cascade or chain reaction that damages 
these acids (Butterfield et al, 2002). Several researchers consider the brain as an organ highly 
susceptible to oxidative damage, and several studies have demonstrated how easy occurs 
the peroxidation of brain cell membranes (Chance, 1979). Also, the brain seems to be more 
susceptible than other organs to peroxidation, this is probably due to its high oxygen 
requirements, it uses 20% of the total oxygen intake, while weighing only 2% of the total 
body weight. Neuronal cells are considered the most susceptible cells to oxidative damage, 
owing to their low antioxidant activity in comparison to other tissues , as well as the high 
content of methyl ions in certain brain regions (Floyd, 1992). In this regard, some authors 
have suggested that the continuous state of oxidative stress may produce specific structural 
alterations of proteins, leading to abnormal protein aggregate formation, which is 
responsible for perpetuating oxidative damage. In fact, these abnormal proteins are 
considered as molecular markers of neurodegenerative diseases such as Alzheimer, 
Parkinson, and Cognitive Dysfunction Syndrome in geriatric dogs (Gallego et, al., 2010a, 
2010b).  
There are several risk factors involved in the development of these neuropathologies, one of 
them is the aging process "per se". In this regard, when the production of ROS / RNS has an 
exaggerated and prolonged increasing, and the antioxidant response is not enough, the 
system reach a different point of equilibrium (homeoresis, rather than homeostasis). This 
equilibrium is accompanied by high concentrations of free amino acids and differences in 
gene expression patterns, allowing survival but causing irreversible neuronal damage in the 
long term (Rivas et al., 2001). The original hypothesis of the free radicals in aging was 
proposed by Harman Gerschman and Harman in the 50´s (Sohal, 1993). The central dogma 
of this theory is that during the aerobic metabolism there is an incidental and uncontrollable 
production of oxygen radical species.  Then, these species promote reactions damaging the 
macromolecules. This irreversible damage accumulates over time and results in a gradual 
loss of functional capacity of the cells (Hayflick, 1993). According to recent studies this 
might be related to neuronal processes of senescence (Passos, et al, 2010).  
2. Oxidative stress (OS) and neurodegenerative diseases (ND) 
There are plenty scientific evidence that considers the brain tissue as a preferential target for 
the accumulation of ROS and RNS, thereby triggering oxidative stress chronic conditions, 
which lead to injury and degeneration of neuronal cells (Contestabile, 2001). It has been 
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reported that the nervous system is rich in iron (Fe3 +) and unsaturated fatty acids 
(Halliwell, 2001), this is one of the main features that make this organ particularly sensitive 
to oxidative stress. Thus, the high lipid content of nervous tissue and its high metabolic 
activity make it particularly vulnerable to oxidative damage (T.M. Dawson & V.L. Dawson, 
1996). It has been reported that iron is essential in the brain, particularly during 
development, but high amounts can lead to the generation of damage to brain cells, because 
Fe 3 + can lead to oxidative stress by catalyzing the formation processes of ROS (Butterfield 
et al, 2002; Gerlach et al, 1994). In addition, the brain consumes a high proportion of the total 
oxygen, since the energy it uses comes almost exclusively from oxidative metabolism which 
occurs in the mitochondrial respiratory chain located in the bodies, dendrites, axons and 
synaptic buttons of cells neural, where the ATPase maintains the ionic gradient across the 
neuronal membrane (Pavón et al., 1998). Another reason that explains why ROS are 
particularly active in the brain is that in this tissue, the metabolism of the aminoacids and 
neurotransmitters acts as an important source of these highly reactive molecules (Uttara et 
al., 2009). Thus, considering that this organ contains low levels of protective enzymes and 
other enzymatic antioxidants, it is easy to understand why their susceptibility (Contestabile, 
2001).  
Although oxidative stress is not the direct cause or the etiological factor responsible for the 
neuropathologies, it is known that it induces toxic effects by oxidizing lipids, proteins, 
carbohydrates and nucleotides. This causes accumulation of intracellular aggregates, 
mitochondrial dysfunction, excitotoxicity and apoptosis. Formation of modified lipids by 
oxidation can cause cellular dysfunction and death in postmitotic cells. Likewise, the 
peroxidation of polyunsaturated fatty acids in cell membranes, initiates a cumulative 
deterioration of membrane functions and causes a decrease in flow, reduction in the 
electrochemical potential and increased permeability of the membrane. Similarly, oxidation 
causes changes in the structure of some proteins and the formation of protein aggregates. 
These abnormal proteins induce oxidative damage that has been observed in 
neurodegenerative diseases as AD and PD. On another hand, ROS also can affect both glial 
cells and neuronal cells, which exhibit a particular sensitivity to free radicals and therefore 
are prone to cell degeneration processes (Gilgun-Sherki et al., 2001). For example, there is a 
biological phenomenon known as "selective neuronal vulnerability", which is involved in 
the response of different neuronal populations against neurodegenerative conditions. For 
example, neurons in the entorhinal cortex, the CA1 region of hippocampus, frontal cortex 
and amygdala, are highly susceptible populations to neurodegeneration associated with 
oxidative stress in Alzheimer's disease (AD) (Braak et al., 1991; Hyman et al, 1984; Terry et 
al, 2001). 
The relationship between aging and neurodegenerative diseases is more than evident. This 
is supported by recent investigations that have observed that during the aging process there 
is an increase in the formation of H2O2 that alters the conditions of the electrons flow in the 
transport chain, facilitating their 'escape' of normal stream flow. This leads the neurons to 
suffer the harmful effect of free radicals. Moreover, studies performed by Sohal, et al., 1993,  
Benzi & Mareti, 1995, and others, have postulated that ROS can inflict damage to the 
mitochondrial inner membrane, the components of the electron transport chain or the 
mitochondrial DNA (mtDNA). Oxidative stress further increases ROS production and, 
consequently, damage to the mitochondria, creating a cycle that perpetuates the effects of 
ROS (González et al., 1999). Thus, it is obvious because aging itself is a key factor in diseases 
such as AD or PD; since the increase of oxidative damage, the progressive mitochondrial  
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failure accumulated with aging, and coupled with the characteristics of brain, make aging 
itself a common risk factor in neurodegeneration. Another fact that may explain the 
relationship between neurodegeneration and aging is that during aging can occurs certain 
level of iron accumulation, which increases oxidative stress. This occurs mainly through the 
Fenton reaction, where the production of highly reactive hydroxyl radicals ends up causing 
damage to DNA, lipids and proteins (Ang et al., 2010; González et al., 1999; Uttara et al., 
2009). 
In addition to the accumulation of free radicals that can occurs in the brain of individuals 
with ND, it is also clear that the antioxidant systems decrease during the aging process. 
Then, the action of ROS turns up in a process even more damaging to neuronal tissue. 
Scientific data suggest that all this deleterious effect seems to be magnified by pathological 
proteins such as beta-amyloid in AD and alpha-synuclein in PD, which act as initiators and 
perpetuators of the intraneuronal oxidative stress, generating injuries and disease-specific 
symptoms. 
2.1 Alzheimer disease 
According to some authors, the ROS in AD induce a prolonged increase pro-oxidant state 
(Benzi & Mareti, 1995). This statement is supported by clinical and experimental evidence 
(for example, high concentrations of Fe and Cu identified in the brains of some patients with 
AD), showing that ROS cause neuronal death and other neuropathological changes 
associated with this disease (González et al., 1999; Ramesh et al., 2010). However, the role of 
oxidative processes in AD is still a matter of debate, with conflicting and divergent data in 
the literature, which could be related to the difficulty of directly measuring the activity of 
ROS in biological systems due to their short half-life and its high reactivity (Gonzalez et al., 
1999). 
Several studies have identified the capacity of the protein ǃA as a chelating agent for 
transition metals (Cu2, Zn2 and Fe3). Regarding this, it is important to note that the binding 
of Cu2 and Fe3 provides free radicals OH ˙, and toxic chemical reactions, due to the altered 
state of oxidation of these two metals, causing the appearance of catalytic H2O2 in the 
presence transition metal (Uttara et al., 2009). Additionally, the Fe3 in AD neurofibrillary 
plaque accumulates (NFT) and depots ǃA, which probably explains the evidence that 
suggests increased levels of Zn (II), Fe (III) and Cu (II) in the neuropil and senile plaques 
(Ramesh et al., 2010). Moreover, it appears that the Fe3 directly involved in plaque 
formation ǃA, and thus indirectly in the formation of ROS, as it promotes amyloidosis by 
modulating the ability of the α-secretase to cleave the amyloid precursor protein (APP), or 
to facilitate the aggregation of Aǃ. 
In 1994, Behl C. and colleagues showed that toxicity in AD is associated with the Aǃ protein, 
which causes increased production of H2O2. These authors also showed that catalase blocks 
the toxicity of Aǃ, which allows us to understand how the H2O2 and its derivatives such as 
OH-radical, cause lipid peroxidation leading to neuronal cell death in this disease (González 
et al., 1999).  In addition, hemoxigenasa1 the Cu\ZnSOD and MnSOD, have been identified 
in neurofibrillary tangles of human brains with AD, suggesting a close interaction between 
ROS and the products from these enzimes. It has also been suggested that cellular toxicity of 
ǃA that is specifically related to damage by ROS or its products, generates insoluble protein 
aggregates, as is known, is a crucial event in AD (González et al., 1999).  
Moreover, there is indirect evidence that ROS can relate to AD. For example, some dietary 
factors such as saturated fatty acids, high calories and heavy drinking have been reported as 
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factors that may increase the risk of dementia and AD. In contrast, consumption of foods 
with antioxidants such as fruits, proteins rich in methionine and vitamins have been 
identified as protective factors against the disease. In this sense, it is possible that the 
variation in the diets may be associated with the prevalence of AD by geographic area, as 
several studies have suggested a link between nutrients of each diet and the presence of 
cognitive changes. However, it is necessary to confirm this experimentally (Ramesh et al., 
2010). 
2.2 Parkinson disease 
Experimental data suggest a relationship between the PD and two mitochondrial-specific 
conditions, dysfunction and oxidative damage to neuronal mitochondria. This assertion is 
supported by research suggesting mitochondrial dysfunction and impairment of 
mitochondrial complex I activity in the neurons of the substantia nigra and frontal cortex in 
PD patients. In addition, several genes whose mutations or polymorphisms increase the risk 
of developing PD are related to mitochondrial function. In this regard, dysfunction of 
mitochondrial complex I, becomes important, since its inhibition creates a biochemical 
environment that increases the production of FMNH semiquinone flavin, which increases 
the generation of O2 and in turn, the latter promotes lipid peroxidation, damage oxidative 
protein and protein nitration mediated by peroxynitrite (ONOO-) and nitrosylation. This is 
a process leading neurons to apoptosis and α-synuclein aggregation with subsequent death 
of dopaminergic neurons. (Navarro & Boveris, 2008, 2010). 
According to Dorado et al., 2003, the substantia nigra has characteristics that tend to make it 
more vulnerable to attack by ROS. These features include low levels of glutathione and 
vitamin E, high levels of free iron (prooxidant), mono amine oxidase (MAO generates ROS), 
NO (radical neurotoxic pro-oxidant) and neuromelanin. The neuromelanin is a black 
pigment found in certain subpopulations of monoaminergic neurons, and is the result of 
auto-oxidation, condensation and polymerization of dopamine and its oxidation products. 
Neuromelanin binds to any neutralizing reactive species, but can become a reservoir of toxic 
under certain conditions (oxidative attack, low levels of glutathione) releases these reactive 
species. Thus, neurons that contain greater amounts of neuromelanin in the substantia nigra 
pars compacta die more easily. 
Glutathione (GSH) which is the most important intracellular molecule for the removal of 
hydroperoxides in the brain, is decreased in Parkinsonian patients. This could be related 
to the increased concentration of MDA (a marker of lipid oxidation). One of the facts that 
suggests the role of ROS in this disease is that they have identified high levels of 
glycosylation end products (AGE resulting from impaired glucose oxidation and cause 
irreversible oxidation of protein) in the substantia nigra and cortex. Also, it appears that a 
factor associated with oxidative damage is that the distribution of transition metals in the 
brain shows large regional differences, so that regions with large amounts of iron (which 
is easily oxidized) as the substantia nigra are at risk of suffer a more aggressive oxidative 
attack (Dorado et al., 2003). However, this is not the only mechanism to explain why 
dopaminergic neurons are especially sensitive to oxidative stress, because its high 
metabolic rate and the oxidation of dopamine, either by autoxidation or by the metabolic 
pathway by means of the MAO (Dorado et al., 2003), they represent a major source of 
ROS. Likewise, dopamine may act as metal chelator electron donors, and owing to its 
tendency towards reduction can initiate the Fenton reaction to generate H2O2. Some 
evidence suggests that mutations in the protein α-synuclein play a crucial role in 
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modulating the activity of dopamine, but negatively, initiating neuronal cytoplasmic 
accumulation and interaction of dopamine with iron to cause the production of ROS 
(Uttara et al., 2009). 
3. Cellular defense systems against oxidative stress (OE) 
ROS and RNS molecules are well known for their deleterious effects on cellular integrity 
and their relation to different neurodegenerative diseases such as described in the previous 
section. However, it is important to note that these molecules also play a physiological role, 
quite distant from the aforementioned pathological role. In homeostatic physiological 
conditions their responses participate in cell signaling systems such as in the defense 
response against infectious agents and induction of mitogenic responses (Valko et al., 2007). 
These cellular responses bring the intra and extracellular environments to a continuous 
exposure to FR (González et al., 1999). Owing to this condition, aerobic organisms have 
evolved specific defense mechanisms, programmed to form cell protective barriers, which 
allow them to restrict the harmful effects of free radicals and neutralize the damage caused 
by the action of these reactive species (D. Almaguer & L.E. Almaguer, 2006; Cadenas, 1997; 
Contestabile, 2001; Perez et al., 2008; Valko et al., 2007; Vian et al., 1999). These mechanisms 
refer to antioxidants. These are molecules of different weights whose function is basically 
delay or inhibit oxidation. The mechanism is to transfer electrons to the reactive species to 
saturate its electron affinity, and thus, maintain ROS at a level compatible with metabolic 
processes and cellular functions (D. Almaguer & L.E. Almaguer, 2006; Contestabile, 2001; 
Viant, 1999). 
3.1 Classification of the main antioxidant systems 
Taking into account specific aspects of antioxidants, such as their chemical nature, 
mechanism of action or origin, several strategies have been proposed for classification. 
According to Gilgun-Sherki et al.2008, these compounds can be classified into two major 
groups: antioxidant enzymes and low molecular weight antioxidants. To the first group 
belong some antioxidant enzyme systems derived from enzymes as cytochrome oxidase, 
superoxide dismutase (Cu-ZnSOD and MnSOD), catalases and peroxidases such as 
glutathione peroxidase and glutathione reductase (Dorado et al., 2003). The group of low 
molecular weight antioxidants involves a variety of antioxidants, so some authors have sub-
classified this group into two: indirect antioxidants (eg, chelating agents) and direct 
antioxidants. The latter group is of great importance in combating oxidative stress and 
contains hundreds of components, however, only a minority of these molecules such as 
glutathione and NADPH are synthesized by the cell itself. 
Another classification for antioxidant systems, refers to its source. In this sense, we can 
identify endogenous antioxidants and antioxidant of exogenous origin. The first group are 
vitamins such as ascorbic acid, tocopherol and retinoic acid also found glutathione in its 
reduced form, coenzyme Q10, melatonin, uric acid and lipoic acid. Also are included some 
isoforms of the enzyme superoxide dismutase (copper/zinc SOD, manganese SOD, 
extracellular SOD), catalase and glutathione peroxidase (Gilgun-Sherki et al.,2008; Chan, 
2001; Contestabile, 2001). With respect to the group of antioxidants of exogenous origin, ie 
those that can only be obtained from external sources, we should mention some substances 
such as acetyl cysteine and carotenoids, which act as precursors of endogenous antioxidant 
type (Gilgun-Sherki et al.,2008; Chan, 2001; Contestabille, 2001). 
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Due to this variety in the classification of antioxidants, a new classification has been 
proposed recently, which seeks to involve the full range of antioxidants based on aspects 
such as chemical nature and mechanism of action (Cui et al., 2004; Pérez, A. et al., 2008). 
Such a classification sets these compounds into the following groups: 
1. Antioxidant enzymes: They act on specific ROS, in order to change them into less 
harmful molecules. Examples of such enzymes are SOD, CAT, and GPx. 
2. Preventive Antioxidants: These bind to promoters of oxidation and sequester transition 
metal ions such as iron and copper, which contain unpaired electrons and greatly 
accelerate the formation of free radicals. Examples of such antioxidants are transferrin 
and lactoferrin (Pauls & Thompson, 1980). Also, ceruloplasmin Cu hijacking to prevent 
the formation of free radicals from peroxides, catalyzes the oxidation of ferrous ions to 
ferric ions due to its ferroxidase activity, and increases the binding of iron to transferrin. 
In addition, the haptoglobins that bind to hemoglobin, hemopexin that binds heme 
groups and albumin binds to heme and Cu (Benedetti et al., 1988). 
3. Antioxidant ROS sequestrant: These inhibit the initiation of chain reactions of free 
radicals or break the chain of spreading it. The main intracellular sequesters are vitamin 
E, carotene and coenzyme Q (Murthy, 2001), while extracellular sequesters include 
protein systems, and water-soluble compounds such as ascorbic acid, uric acid and 
bilirubin (Cui et al, 2004; Frei et al., 1988; Pérez, A. et al., 2008;). 
4. Nutritional Antioxidants: Diet is the major source of substances with antioxidant 
properties or elements for the synthesis of antioxidant enzymes. Several metals (copper, 
zinc, selenium, manganese, iron) are involved as components or cofactors of numerous 
enzymes antioxidants, and certain vitamins (ascorbic acid, α-tocopherol and ǃ-carotene, 
folic acid) act as a sequestrant of ROS (Pérez, A. et al., 2008). 
3.2 Mechanisms of neutralization of ROS 
The different antioxidant systems work in a coordinated manner, following a series of 
metabolic processes where O2-metabolized by superoxide dismutase SOD generates 
H2O2, and this in turn is metabolized to H2O and O2 by a catalase or  glutathione 
peroxidase, which act as coupled with glutathione reductase (Dorado et al, 2003). However, 
it is difficult to think of a single molecular mechanism that acts as a regulator of the 
generation and the effects of FR, so some authors, for instance, Cadenas, 1997, propouse at 
least three types of molecular mechanisms that underlie the activities of various 
antioxidants. Such mechanisms are: (a) a process involving the transfer of the radical nature 
of ROS, together with the formation of a reactive radical, an antioxidant derived previously, 
(b) a similar process in which the transfer of the radical, and the formation of a stable or 
inert radical is carried out through enzymatic activity, and (c) mechanisms of action of small 
molecules that mimic the activity of enzymes such as SOD and GPx. These mechanisms 
describe to some extent the action of a variety of molecules with antioxidant properties, for 
example, enzymes such as SOD, CAT and GPx, which are responsible for initiating the 
process of neutralization of ROS by the dismutation of O2 to H2O2 (D. Almaguer & L.E. 
Almaguer, 2006). Other defense mechanisms used by different antioxidants include, 
recycling of ROS/RNS or their precursors, inhibition of ROS formation, binding of metal 
ions required for catalysis of ROS generation and activation of endogenous antioxidant 
defenses (Gilgun-Sherki et al.,2008). 
According to some researchers (Halliwell, B., 1994, 1997; Cadenas, 1997; Dorado et al, 2003), 
the protective efficiency of this variety of antioxidants, is somewhat dependent on the type 
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of ROS generated, the place where they are produced (physical barriers like the blood-brain 
barrier permeability reduce many antioxidants) and the severity of cell damage. 
4. Antioxidants and neurodegeneration 
During the last decades in many populations around the world there has been a notable 
increase in the number of adults over 60´s (United Nations [ONU], 2009). Consequently, 
there has been an increase in the incidence and prevalence of various diseases affecting the 
elders. Among this group of diseases, the neurodegenerative type have become very 
important, especially in industrialized countries, which are listed as the third leading cause 
of death after cardiovascular diseases and cancer (Boyd, 2000; Gallego et, al., 2010a; United 
Nations [ONU], 2009; Segura, 2003; Troenes B, et al 2003). However, the ND related to 
aging, not only represent a problem for human health because there are substantial data 
showing that aging also predisposes other species to suffer dementia syndromes. For 
example, some old dogs can develop neuropathology similar to AD, known as Cognitive 
Dysfunction Syndrome in Senior Dogs (CDS) or "dog´s Alzheimer". This disease affects dogs 
over 7 years old and due to its clinical and pathophysiological similarities with AD has been 
proposed as a model for doing research in the field of neurodegeneration, especially in the 
study of AD (Adams B, et al., 2000; Gallego, 2010b; Overall, 2001; Ruehl et al., 1995). 
As already mentioned, the incidence of ND increases with age, however, we must clarify 
that the risk of having them can be determined, partially, by factors such as lifestyle, obesity, 
metabolic syndrome, genetic susceptibility, predisposing medical factors and increased 
oxidative stress, among others, but the last one is the main factor related to the presentation 
of these diseases (Contestabile, 2001; James et al., 2009; Kelsey et al., 2010; Uttara et al., 
2009;). In this sense, today it seems clear the role of oxidative stress during the onset and 
course of ND associated with aging (Meydani et al., 1998; Passos et al., 2010). So, 
recognizing this fact has allowed us to identify therapeutic targets where the activation of 
cellular mechanisms of antioxidant type appear to be a suitable option for the treatment of 
neurodegenerative diseases such as AD, PD and CDS (Casetta et al., 2005; James et al., 2009, 
Contestabile, 2001). In general terms, the main goal of the antioxidant therapy for these 
diseases is to interrupt or modulate the interaction of pathological neuronal protein (Aǃ 
protein and Tau protein) with redox metals. This is in order to prevent damage or 
decomposition of metalloenzymes, and innate antioxidant systems by promoting 
homeostasis of metals and minimizing the OE and its effects (Uttara et al., 2009). 
Additionally, several studies suggest that increasing cellular protection through the use of 
antioxidants could be beneficial for maintaining or reducing the rate of neuronal death 
during the course of certain ND, such as PD (Casseta et al., 2005; Kelsey et al., 2010). 
Thus, taking into account the growing interest in antioxidant therapy for the treatment 
and/or prevention of ND, and considering that diet is a main source of natural Anti-
Oxidants (AO), then we present a systematic review of scientific evidence showing the 
action and effect of some food products on the course or the beginning of the characteristic 
lesions of this type of pathology. 
4.1 The role of diet as a preventive factor against the development of ND 
Given that the lifestyle and the type of diet can act as important risk factors for the 
emergence of various diseases (Kalaria et al., 2008), the relationship between a particular 
diet and its effects long-term research center have been some authors who seek through diet 
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and antioxidant compounds, mechanisms to develop or enhance protective responses 
against a constant state of oxidative stress. In addition, people generally consider that there 
are several advantages to the use of antioxidants, in fact, there are a consumer culture 
around these compounds, where people attempt to consume diets rich in antioxidants 
and/or supplement their diet with one or more of these substances to "improve living 
conditions for the geriatric stage" (Mullie et al., 2009). Several studies have shown that diet 
has a long-term effect on general health (Leibson et al., 1997; Uttara et al., 2009; Vermeer, et 
al., 2003), acting as a principal source of natural antioxidants due to its ability to provide a 
variety of molecules that activate or enhancer the action of some endogenous antioxidants 
(Sun et al., 2008). In this sense, it is important to consider the effect of these molecules on 
processes of neuroprotection, since according to some reports, the diet also has the ability to 
extend human cognitive longevity (Peter, et al, 2004; Casseta, 2005, Glade, 2010; Ramesh et 
al., 2010). There are several antioxidant research in the field of ND, such as AD and PD, but 
despite the variability of results and poor clinical trials, diets rich in vitamins and other 
natural antioxidants still seem to be publicly recognized for their action as useful 
supplements in reducing risk of suffering some types of dementia (Kamphuisa & 
Scheltensb, 2010). 
Evidence of this can be seen in some studies indicating that Indian diets, which contain 
spices like red chilli, coriander and turmeric (plant widely used as food preservative and 
medicinal), apparently reduced the prevalence of patients with AD in India, since its 
incidence is 4.4 times lower compared to countries like the U.S. (James et al., 2009; Ramesh 
et al., 2010). Additionally, some reports indicate supplementing diets high in fat that 
usually lead to the development of cardiovascular diseases with a high intake of dietary 
antioxidants, such as polyphenols, may reduce the risk of disease. Likewise, consumption 
of nutritional substances such as berries, nuts or fish oil can dramatically impact on the 
aging brain, possibly leading to improved motor and cognitive skills (James, et al, 2009). 
In this context, the interest in finding low-cost therapeutic alternatives that improve living 
conditions and reduce the risk of age-related diseases has led to the identification of a 
growing list of antioxidant supplements as Vitamins C and E, ǃ-carotene, coenzyme Q, 
ascorbate and polyphenols, among others (Burton & Ingold, 1989, 1990; Kelsey et al., 
2010). 
4.2 Scientific evidence of AO supplementation in the treatment of ND 
Natural antioxidants can act as a therapeutic tool against excess ROS, because several of 
them have a high ability to cross the blood brain barrier (Uttara et al., 2009), and can 
activate various antioxidant mechanisms in the brain in order to create conditions to 
achieve and maintain the neuronal homeostasis (Gilgun-Sherki et al., 2001). However, an 
antioxidant substance that has some use in preventing the ND must have some additional 
capabilities to its ability to sequester free radicals. For example, one of the main AO found 
in mammalian cells is glutathione (GSH), however, this substance, despite its large capacity 
anti FR can´t be directly used for supplementation, due to their inability to cross the blood-
brain barrier and reach the brain tissue (Witschi et al., 1992). Despite this, some of its 
precursors or analogs have been tested in various animal models (Contestabile, 2001). 
Thus, studies such as Martinez, et al., 2000, suggest that long-term supplementation with 
GSH precursors such as N-acetylcysteine can partially restore the impaired memory and 
decreased mitochondrial lipid peroxidation, characteristic of aging process. (Contestabile, 
2001; Prasad  et al., 1999).   
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The use of AO decreases oxidative damage and also reduce the cognitive decline associated 
with age, this in both human and animal models (Joseph et al., 1998; Milgram et al., 2002). 
Examples are the studies conducted in geriatric dogs, which indicate that oxidative damage 
may be related to cognitive dysfunction and that long-term treatment with AO, with a 
behavioral enrichment program, reduce cognitive decline in dogs CDS (Cotman et al., 2002; 
Gallego et al, 2010a; Head E, 2002; Landsberg, 2005). Also, some authors argue that the 
intake of fruits and vegetables may reduce the risk of cognitive decline associated with 
aging in rodents, dogs and even humans, attributing that property to the capabilities of 
some antioxidants and anti-inflammatory compounds found in these foods (Araujo et al., 
2005; Gallego et al., 2010; Landsberg, 2005; Opii et al., 2008).  
With regard to vitamins, their results seem contradictory. Studies conducted with various 
vitamins have suggested these compounds as potential protective factors against states of 
neurodegeneration. Thus, recently demonstrated that supplementation of Vitamin E 500UI 
long term in the rats diet can protect against cognitive decline associated with aging (Morris, 
et al., 2005; Peterson et al., 2005). However, other studies in this category showed 
contrasting results, for example, a research conducted by Young KW, et, al, 2005, which 
included subjects with mild cognitive impairment, who were given a daily dose of 2.000UI 
of Vitamin E and 10 mg of donepezil (compound with anticholinergic activity) or a placebo 
for a period of three years. The results of this study showed that the overall rate of 
progression from mild cognitive impairment to clinical expression of AD was 16% per year, 
and no difference was found between the subjects who were administered placebo, and 
subjects who received vitamin E, suggesting a disagreement over the validity of vitamin 
supplements to patients with AD (Kelsey et al., 2010).  
With respect to the PD, some of the AO compounds that have been suggested as protective 
factors include vitamins A, C (3000 mg/d) and E (3200 mg/d) (Fahn, 1991). Several 
epidemiological studies have shown that consumption of these vitamins may improve 
cognition and reduce the risk of developing clinical symptoms characteristic of this disease 
(Masaki et al., 1994). Likewise, the study by Chen et al, 1997, showed that administration of 
coenzyme Q10 improved clinical symptoms in patients with mitochondrial encephalopathy. 
Similarly, Birkmayer, et al, 1990, in a study of 415 patients with PD showed that 
administration of a dose of 1.4 mg/kg NADH can be an effective therapeutic tool in the 
treatment of PD. According to some authors, the efficiency of AO such as vitamins E and C, 
is the most convincing evidence of the involvement of free radicals in PD. However, in order 
to determine the efficacy of an antioxidant treatment, it is necessary to perform additional 
studies including high doses of vitamin E (3200 mg/d) in combination with vitamin C  
(3000 mg/d), before the administration of levodopa in patients with early PD (Fahn, 1991; 
Rao & Balachandran, 2002). 
Acetyl-L-carnitine as a metabolite of vitamins involved in the process of synaptic 
transmission and has a potent neuroprotective effect can reduce the structural damage 
caused by states of oxidative stress in neurons. Neuroprotective capacity of this metabolite 
is evidenced through the increase in resistance to oxidation of cellular components such as 
mitochondrial RNA, and various proteins (Sharman et al., 2002; Poon et al., 2006). Previous 
research has shown that the brains of old rats respond positively to the diets supplemented 
with acetyl-L-carnitine in the long term. This effect is generated by activating the expression 
of intracellular enzymes such as GSH and SOD, which leads to a reduction in the formation 
of 4-hydroxynonenal in the mitochondria, and thus decreases the degree of carboxylation 
and oxidative nitrosylation mitochondrial protein (Calabrese, et al., 2006; Poon et al., 2006).  
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Additionally, some authors suggest that the severity of demyelination and neuronal necrosis 
is reduced in brain areas such as cortex, hippocampus, cerebellar cortex and optic nerve of 
rats consuming acetyl-L-carnitine (Ramacci et al., 1998; Glade, 2010). Likewise, the use of 
acetyl-L-carnitine as a dietary supplement to improve cognitive longevity has been 
demonstrated by the results of a study by Passeri et al., 1990, in which two parallel groups 
and assessed homogeneous subjects of both sexes aged 65 years and with mild cognitive 
functions. One group was supplemented with 2 gr/day of acetyl-L-carnitine for three 
months, while the other group was treated with a placebo. The group of patients treated 
with acetyl-L-carnitine showed a significant improvement in learning abilities, and long-
term memory skills, suggesting the therapeutic importance of this metabolite for the 
treatment of geriatric patients with mental disfunction.  
Besides the natural AO, there is also a growing list of synthetic AO that have been widely 
studied, for example, conjugated forms of the enzymes SOD and CAT (Greenwald, 1990) 
and supplements of selenium (Parnham et al., 1991). Similarly, there is growing evidence 
that give, some drugs with different therapeutic uses to neuroprotection such as probucol 
(hypocholesterolemic) and salicylates, a certain capacity as recycler of free radicals under 
experimental conditions (Cui et al., 2004; Juliano et al., 1995; Zhao et al., 1995). 
However, despite the existing literature suggesting beneficial effects of AO, there are 
several questions regarding the therapeutic value that some natural AO may have 
compared to pathological processes such as AD and PD. There are conflicting data 
emerging from research on in vitro and in vivo neurodegeneration models, and some 
authors argue that the fact that one type of antioxidant molecule is produced 
physiologically or is taken normally from the diet is not a guarantee that this 
supplementation can be safe and advantageous therapeutic standpoint, since it must be 
took into account the physiological regulation of the redox state of the cell (Contestabile, 
2001). In conclusion, experimental data are converging in terms of the therapeutic benefits 
of various natural antioxidants with neuroprotective capabilities, however, according to 
some authors, there are very few clinical data to demonstrate a clear and lasting effect of 
this type of treatments. Some possible reasons for such a disadvantage might be specific 
criteria such as dose, stability, duration of treatment, side effects and ability to cross the 
blood brain barrier, among others (Contestabile, 2001; James, 2009; Meydani et al., 1998). 
Because of this, it is essential to expand research on the use of AO diet supplements 
compared to the onset and development of ND as AD and PD. 
4.3 Dietary supplements with antioxidant used in the management of ND 
Considering the cascade of degenerative events of diseases such as AD and PD (degradation 
and abnormal folding of proteins, inadequate energy production in CNS degeneration by 
oxidative damage, excitotoxicity and inflammation), there is interest in whether the AO, or 
changes in eating habits can prevent and/or block one or more of these pathways of 
neurodegeneration in slowing the progression of the disease (Mazzio, et al., 2011). In this 
regard, several studies have suggested some properties of antioxidants as protective factors 
against the risk of diseases such as AD and PD. In addition, it is considered that changes in 
the concentration of AO in states of neurodegeneration may be a primary event or 
secondary to the ingestion of a particular type of diet (Kedar, 2003). Therefore, considering 
the usefulness of certain AO and its possible uses in therapy of ND, the following describes 
some of the main AO that are consumed in the diet or supplemented in order to treat or 
prevent the onset of neurodegenerative conditions such as AD or PD. 
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4.3.1 Vitamins 
4.3.1.1 Vitamin E 
Vitamin E or tocopherol is a powerful antioxidant capable of stopping the spread of the 
chain reaction of free radicals in the lipid portion of cell membranes, inhibiting lipid 
peroxidation in plasma membrane phospholipids (Mandel et al., 2003; McCay, 1985; Gilgun-
Sherki et al., 2001). There are eight tocopherols with vitamin E activity, and α-tocopherol is  
 
Use Results Reference 
The individual or combined action 
of tocopherols are protective 
factors against the incidence of AD 
and cognitive dysfunction 
The different forms of tocopherol that 
make vitamin E exert greater 
protective effect associated with AD, 
compared with α-tocopherol alone 
Morris et 
al. 2005 
Supplementation with vitamins E 
and C to reduce lipid peroxidation 
in patients with AD. 
Increases in plasma levels of vitamin 
E does not affect the oxidation 
resistance of lipoproteins, it is 
necessary to use combinations of the 
two vitamins. 
Kontush et 
al. 
[281], 
Supplementation with 3000 IU / 
day vitamin E and C can delay the 
onset of symptoms associated with 
dopamine deficiency in PD 
patients 
Increase the time interval between 
the onset of the disease and the need 
for treatment with L-dopa in 75% of 
patients. 
Fahns A, 
1998 
Combination of supplements of 
vitamins C and E affect the 
prevalence and incidence of AD. 
The combined use of vitamin 
supplements showed a decrease in 
the incidence and prevalence of AD 
in a population of 5092 individuals 
Zandi et 
al., 2004 
Supplementation with 2000 IU / 
day vitamin E reduces the EO 
implicated in the pathogenesis of 
AD. 
Treatment delays functional 
impairment in patients with mild 
Alzheimer's disease. 
Sano et al., 
1997 
High doses of α-tocopherol and 
ascorbate can delay the time of 
administration of L-dopa in PD 
patients 
The combination of these natural 
antioxidants delayed by 2.5 years, the 
time for the start of the 
administration of L-dopa in PD 
patients. 
Fahn S, 
1991 
Long-term supplementation with 
vitamin E may provide cognitive 
benefits. 
No differences were found between 
groups treated with vitamin E and 
placebo groups 
Jae Hee 
Kang, 2006 
The intake of high doses of 
vitamin E (400-4000 IU / day) can 
slow the progression of PD by 
inhibiting nigral cell death 
No increased levels of vitamin E in 
the cerebrospinal fluid of patients 
with PD. However, the subjects had 
clinical symptoms of the disease 
when vitamin E was administered. 
Pappert, 
E.J 
Table 1. Vitamin E or Tocopherol starring in several studies evaluating the antioxidant 
supplementation and its effects on cognitive deficits related with ND 
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the most active and widely distributed (Elejalde, 2001); it is found naturally in foods such as 
vegetable oils, fats, vegetables, egg yolks, nuts, seeds, fruits and green vegetables (Berman & 
Brodaty, 2004). In addition to its antioxidant properties, also has capabilities such as specific 
enzymes regulating agent, anti-inflammatory and neuroprotective (Martin et al., 1999). Due 
to its neuroprotective properties, researchers worldwide have taken a particular interest in 
elucidating their protective mechanisms, as opposed to development of cognitive 
dysfunction related to aging and various ND (Table 1) (Ramesh et al, 2010). 
The neuroprotective effect of vitamin E was first described in 1992 in an in vitro study using 
neuronal cells cultures (Behl C, et al, 1992). However, in order to know whether dietary 
supplementation with antioxidants can increase their brain levels, it is essential to 
investigate the effect of such molecules in animal models of ND like the EP (Prasad et al., 
1999). In this regard, previous studies suggest that long-term feeding of rats (6 to 15 months 
of age) with a dietary supplement of 500 IU of vitamin E, induces protective effects against 
cognitive deficit related to age (Morris et al., 2005; Peterson et al., 2005). Similarly, it has 
been reported that supplementation with vitamin E in combination with vitamin C, 
increases the concentration of these vitamins in plasma and cerebrospinal fluid, where the 
resistance of lipoproteins to oxidation in in vitro studies is increased (Kontush et al, 2001; 
Casetta et al., 2005). It has also been reported that dietary supplementation with α-
tocopherol (1000 IU/day) for four months increases brain levels of vitamin E in rats 
(Vatassery et al., 1988), as in the brain and cerebrospinal fluid of dogs treated during two 
years (SR Pillai, 1993). These results suggest that dietary supplementation with vitamin E 
may be valuable in animal models of PD (Prasad et al., 1999). 
On the other hand, one of the largest studies with antioxidants as a treatment for AD, 
included 341 patients with moderate dementia who were given 4 different treatments: 
10mg/day of selegiline (a selective MAO inhibitor), 2000 IU daily α-tocopherol, a 
combination of selegiline and-tocopherol, or placebo. The effect of the treatments was 
assessed through the presentation of clinical signs such as loss of ability to perform basic 
activities of daily living, severe dementia or death. After the treatments the authors 
observed a significant delay in the time of presentation of clinical signs in patients treated 
with selegiline, alpha-tocopherol, or in combination compared with placebo (Sano, 1996, 
1997). However, there was no additive effect of selegiline and vitamin E, possibly due to a 
common mechanism of action in which lower levels of free radicals, and prevents its 
formation through inhibition of oxidative metabolism of catecholamines (Casetta et al., 
2005). Similarly, studies by Behl, C., 2000, suggest a neuroprotective activity of both, the 
natural tocopherol and the synthetic. In addition, the effect appears to be superior to that 
described for estradiol (powerful antioxidant), in terms of the ability of neuronal protection 
against oxidative damage generated by ǃ-amyloid protein in AD. Additionally, there are 
studies that seek to enhance the antioxidant effect of tocopherol, in combination with other 
vitamins such as Vitamin C. For example, in a prospective study in the Netherlands 
(Engelhart et al., 2002), they used a population of 5395 subjects at least 55 years, where the 
high intake of vitamin C and E was associated with a lower risk of developing AD after a 
follow up of 6.5 years. The relative risk was 0. for vitamin E, and 0.82 for vitamin C (Casetta 
et al., 2005). 
With respect to the source, the vitamin E supplements do not appear to offer better results 
than those obtained by eating foods rich in this vitamin (Kontush & Schekatolina, 2004). This 
may be due to the cumulative and synergistic, as the bioavailability of vitamins is 
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concerned. However, not be ruled out that the apparent protection provided by the 
supplementation of vitamins E and C, is the result of the synergy of these vitamins and 
other substances in fruits and vegetables such as flavonoids, which have both anti-
inflammatory properties as antioxidants (Ramesh et al., 2010; Seshadri & Wolf, 2003). It has 
also been suggested that vitamin E supplements can reduce levels of ǃ-amyloid in a 
transgenic model of AD. However, this effect was only observed in young mice but not in 
older animals. These results may suggest that antioxidant therapy may be beneficial only if 
given at an early stage of the disease (Sung et al., 2004; Casetta et al., 2005). 
The inconsistencies found between the results of these and other studies of vitamin E, lead 
to consider that most supplements used are composed exclusively of α-tocopherol, leaving 
aside the action of other forms of tocopherol that make this vitamin. Therefore, it has been 
suggested that the protective effect of vitamin E in the brain is the result of the combined 
intake of all forms of tocopherol (Farrell &  Roberts, 1994). 
4.3.1.2 Vitamin C 
Vitamin C or ascorbic acid is a soluble molecule that has a variety of functions, which 
include the recycling of oxidized forms of vitamin E and the activation of certain enzymes 
(McCay, 1985; Chan, 1993; Elejalde, 2001). Importantly, in vivo there are interactions 
between vitamin E and vitamin C, where the role of antioxidant vitamin E has proven to be 
improved by supplementation of vitamin C. This interaction, however, involves the two 
vitamins, whose levels are not regulated by metabolism, but depend on consumption in the 
diet (Kagan, & Tyurina, 1998). Humans and other primates are unable to synthesize this 
vitamin, while most mammals, including rats and mice produce the endogenous form of 
this molecule in the liver (Chatterjee et al., 1975). 
Vitamin C is found at high levels in a variety of cells, including neurons, where it 
participates in the biosynthesis of catecholamines and plays an important role as a cofactor 
of dopamine-hydroxylase. Vitamine C and vitamin E inhibit peroxidation of membrane 
phospholipids and act as free radicals scavenger (Gilgun-Sherki et al., 2001). Some authors 
report that ascorbic acid protects low density lipoprotein from oxidation and reduces 
oxidizing molecules that damage the integrity of the Central Nervous System (Sales et al., 
2009). Given these properties, the scientific interest in this vitamin is to know about their 
effects on neuronal damage induced by agents such as pilocarpine, where has been found 
that antioxidant treatment significantly reduces the level of lipid peroxidation and nitrite 
content, and also potentiates the activity of SOD and CAT in the hippocampus of adult rats 
after pilocarpine-induced seizures. (Sales et al., 2009). 
With respect to the ND, Hellenbrand et al., 1996, found that vitamin C has a protective effect 
against PD, with statistically significant trend. Several studies in populations aged 65 or 
older focused their interest on the combined effect of vitamin C and other antioxidants such 
as vitamin E, beta-carotene, or flavonoids, and these could be associated with reduction of 
dementia / incidence of AD or reduction of cognitive decline (Esposito et al, 2002; Coley et 
al., 2008). Zandi et al., 2004 reported that using the combination of high doses of vitamins E 
and C are associated with reduced prevalence and incidence of AD, even, once initiated the 
disease. 
4.3.1.3 Vitamin B  
B complex vitamins such as thiamin (vitamin B1), lipoic acid, biotin, vitamin B6, folic acid, 
vitamin B12, pantothenate, symbiotically work together to boost the pyruvate dehydrogenase 
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complex, and the contribution of gluconeogenesis oxygen to the brain. In addition, due to 
the critical role that these nutrients play in the metabolism of glucose and mitochondrial 
respiration justifies the use of B vitamins for patients with PD (Mazzio et al., 2011). Some 
authors argue that a relationship exists between the PD, vitamin B6, vitamin B12 and folic 
acid. This relationship refers to the role played by these molecules in the regulation of 
homocysteine, since they are responsible for their cleavage to methionine and 
tetrahydrofolate. Such effects may attenuate the neurotoxicity associated with a condition 
known as hyperhomocysteinemia, which is associated with PD and cytotoxicity related 
Mitochondrial Transitory Permeability Pore (Mazzio et al., 2011). Additionally, it has been 
suggested that elevated levels of homocysteine may increase the severity of PD, since this 
amino acid could mediate neuronal toxicity through NMDA receptors, precipitating 
oxidative stress, calcium overload and apoptosis (Mazzio et al., 2011). Homocysteine has 
also been associated with states of oxidative stress related with AD. In fact, there are some 
reports of an increased intake of vitamin B6 (Tucker et al., 2005; Corrada et al., 2005), 
vitamin B12 or folate (Wang et al., 2001; Morris et al., 2005), in middle-aged or advanced age 
people, with the belief of obtaining a beneficial effect on the incidence of AD or cognitive 
impairment (Coley et al, 2008). 
In this regard, several studies seeking to assess the impact of high doses of vitamin 
supplements on plasma homocysteine levels in patients with AD (Aisen et al., 2003). For 
example, a study in patients with AD evaluated the effects of supplementation of these 
individuals over a period of 18 months. The results indicated that the groups treated with 
high doses of folic acid, vitamin B6 and B12 reduced by 20-30% peripheral levels of 
homocysteine, however, the study showed no cognitive differences between individuals 
treated with antioxidants and individuals treated with placebo (Aisen et al., 2003). 
4.4 Polyphenols  
As mentioned above, the use of vitamin supplements may promote the biological integrity 
of systems, however, the combined use of vitamins and plant-derived polyphenolic 
compounds, seems to have good recognition as antioxidants (Mazzio et al., 2011). The use of 
supplements from plants to improve health is an issue that is gaining popularity among 
most people because it is considered that the use of natural products is safe and produces 
fewer side effects, compared to synthetic drug, in fact, to date over 50 different species of 
plants, and more than 8000 phenolic compounds have been identified with beneficial effects 
on health (Sun et al., 2008). 
Polyphenols can be divided into different groups depending on the number of rings of 
phenol and the chemical group attached to these rings. The most representative of this 
group of substances are the flavonoids, which are subdivided into flavonoids (catechin, 
epicatechin), flavonols (quercetin, myricetin, kaempferol), flavanones (hesperetin, naringenin), 
flavones (apigenin, luteolin), isoflavones (genistein, daidzein) and anthocyanins (cyanide, 
malvidin) (Ramassamy, 2006; Sun, et al., 2008). These molecules are found in a wide variety 
of food products from plants. One of the most important aspects of the polyphenols current 
research is their neuroprotective capacity. This section will define and describe in detail the 
neuroprotective mechanisms of these macromolecules, and also, will discuss recent evidence 
regarding their potentially antioxidant effect to prevent or to control the development of 
neuropathology as AD or PD. 
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4.4.1 Plant polyphenols 
Polyphenols are a class of phytoalexins found in a wide range of plants, fruits and 
vegetables (Bastianetto & Quirion, 2002; Brannon et al., 2010; Ramassamy, 2006; Ramesh et 
al., 2010). When ingested they are transported from the circulatory system to various body 
organs including the brain (Sun et al., 2008). It has also been found to be potent recyclers of 
superoxide radicals, hydrogen peroxide and oxygen (Morel et al., 1993; Nanjo et al., 1996; 
Ramassamy, 2006), mechanisms that together with the anti-inflammatory activity have been 
extensively studied in order to know their beneficial effects against aging-related processes 
(Table 2) (Brannon & Trygve, 2010; James et al., 2009). 
The ability of polyphenols to act as antioxidants is given by its ability to chelate metal ions, 
which is achieved by suppressing reactive species that contribute to oxidative damage 
(Brannon & Trygve, 2010). This antioxidant capacity depends on the molecular structure of 
each polyphenol, the position of hydroxyl groups, and other substitutions in their chemical 
structure (Sun et al., 2008). In addition to the antioxidant capacities, several polyphenols 
exhibit multiple biological properties among which are the anti-inflammatory, anticancer, 
antiviral, antimicrobial, vasodilator and anti-coagulant (Rahman et al., 2007). Additionally, 
in vitro studies demonstrate that polyphenols may possess the ability to activate or inhibit 
several signaling pathways such as NF-κǃ, SIRT1, MAPK's, heat shock proteins and other 
regulatory molecules, which may play an important role in basic functions such as 
senescence, apoptosis and the activation or production of transcription factors (Brannon & 
Trygve, 2010).  
Furthermore, polyphenols are natural antioxidants that after consumption tend to produce 
an increase in plasma antioxidant capacity, and also can inhibit the oxidation of low density  
 
Polyphenol Effect Result 
Resveratrol Activation of SIRT1 driving to 
deacetylation of p53, NF-κǃ, HSF-1, 
FOXO1/3/4 y PGC-1α. 
Activation of SIRT1 can mimic 
caloric restriction  
It binds to receptors in the brain to 
stimulate the production of 
transthyretin (TTR) 
Influence on senescence, 
inflammation, apoptosis, resistance 
to stress and  metabolism 
Increment of half life 
TTR sequesters beta-amyloid fibrils 
EGCG Regulates NO production in 
endothelial cells 
Regulates NO production in 
carcinoma cells 
Blocks EGF receptor in cervical 
cancer cells 
Prevents inflammation associated 
with atherosclerosis 
 
Prevention of metastasis 
Prevention of tumor growing 
Quercetine Regulates production of TNF-α Anti-inflammatory properties that 
reduce development of 
atherosclerosis. 
Table 2. Attenuation of diseases associated to aging by action de polyphenols (Brannon & 
Trygve, 2010) 
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lipoprotein. These features have drawn public attention, since several of these substances 
have therapeutic potential against diseases such as cancer, ischemia, heart, liver, and 
neurodegenerative diseases (Mandel et al., 2003). Thus, numerous studies in different 
models of neurodegeneration in vitro and in vivo have shown that polyphenols can prevent 
and/or reduce oxidative damage by free radicals generated (Mandel & Youdim, 2004; 
Scalbert et al., 2005). Numerous epidemiological estudies have shown neuroprotective 
effects of polyphenols and have established a clear relationship between these effects and 
decreased risk of neurological dysfunction associated with aging (Mandel et al., 2003). 
However, the nature of these protective effects, is not limited to the antioxidant properties, 
since recent evidence derived from in vitro cellular models, suggest that polyphenols such as 
resveratrol and EGCG, besides having the ability to recycle free radicals directly, also may 
regulate the cytotoxic effects of oligomers of ǃA via phosphorylation of phosphokinase C. In 
addition, polyphenols such as EGCG and resveratrol possess the ability to activate the 
enzyme transmembrane α-secretase, which catalyzes the formation of a soluble and 
amyloidogenic (no plaque-forming) from the amyloid precursor protein (APP). Through this 
pathway, APP is formed and therefore do not allow the formation of neuritic plaques, a 
hallmark of AD. This information indicates that polyphenols may be used in therapies to 
exert control over the APP related molecules, and may suggest avenues for the development 
of new treatments that reduce the risk of developing AD according to the aging process. 
(Brannon & Trygve, 2010). 
Additionally, studies such as James et al., 1999, showed the extracts of blueberry or 
strawberry (high in polyphenols) as substances that can significantly attenuate cognitive 
and motor deficits related to aging in rodents. In this study, rodents of all treatments 
showed improvement in short-term memory according to the Morris water test. However, 
while these diets were supplemented based on an equal antioxidant capacity (determined 
by absorbance capacity test the oxygen radical, ORAC) was not found equal effectiveness in 
the prevention or reversal of the changes associated with aging. Additionally, the 
antioxidant capacity alone was not predictive in evaluating the potential of these 
compounds against certain age-related disorders. In fact, markers of oxidative stress (DCF 
fluorescence, and glutathione peroxidase level in the brain) were slightly reduced by the 
diets, suggesting that the polyphenols from berries can have multiple actions in addition to 
the antioxidant. 
Other possible mechanisms for the beneficial effects of these foods are: direct effects on 
signaling to enhance neuronal communication, the ability to act as a buffer against excess 
calcium, enhancement of neuroprotective proteins and reduction of signs of stress such as 
NF -κǃ. (Calabrese et al., 2010). According to studies in cell cultures and animal models, 
there is a cascade of signaling between the molecules and effects of eating berries. For 
example, treatment with berries to COS-7 cells exposed to dopamine or to hippocampal 
primary neurons, significantly increased the expression of MAPK mitogen. Additionally, 
mice supplemented with berries APP/PS1, exhibited high levels of hippocampal 
extracellular signaling regulated by ERK, such as protein kinase C (PKC) α, compared with 
transgenic mice maintained on control diets. In addition, Brannon & Trygve, 2010, suggests 
that treatment with berries is effective protection against the toxic effect of ǃA and against 
the decline in the induction of dopamine in the regulation of intracellular calcium in COS-7 
cells transfected hippocampal neurons. This protection suggests an increase in 
phosphorylated MAPK and decreased PKCǄ.  
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4.4.1.1 Epigallocatechin 3-Gallate (EGCG)  
EGCG is a polyphenol flavonoid type found in large quantities in green tea. According to 
some authors, this compound has exerts significant neuroprotective effects against a wide 
range of oxidative insults in a multitude of neuronal cell models (Calabrese et al., 2010; 
Kelsey et al., 2010). In one study, CGNs incubated cells with an inhibitor of Bcl-2 known as 
HA14-1, which generates oxidation and mitochondrial intrinsic apoptosis (Zimmermann et 
al., 2007), applying the co-treatment with EGCG, was found that the microtubule network of 
CGNs exposed to HA14-1 was significantly preserved, and so, was prevented the apoptotic 
nuclear morphology (Kelsey et al., 2010). In fact, studies like that of Weinreb et al., 2004, 
showed that treatment of neuronal cells with EGCG affects the expression levels of various 
proteins, including proteins related to components of the cytoskeleton, metabolism, and 
binding proteins (Calabrese et al., 2010; Izumi et al., 2005). EGCG similarly protects human 
neuroblastoma cells (SH-SY5Y) against the cytotoxicity associated with the amyloid 
precursor protein (APP), and the 6-hydroxydopamine (6-OHDA) (Avramovich et al., 2007), 
thus, rescues PC12 cells from serum deprivation-induced apoptosis or paraquat (Hou et al., 
2008; Kelsey et al., 2010; Mandel et al., 2003). Also, supplementation of transgenic mice over 
expressing APP (APPsw) substantially reduced amyloid plaque burden and reduced 
cognitive impairment (Rezai-Zadeh et al., 2005, Kelsey et al., 2010). Similarly, in murine 
N2A cells transfected with a mutant form of human APP (Rezai-Zadeh et al., 2005) was 
found that EGCG reduced the generation of ǃ-amyloid (Ramassamy, 2006).  
In addition to the neuroprotective effects of EGCG observed in in vitro studies, this 
antioxidant also preserved neuronal survival and function in several in vivo models of 
neurodegeneration. For example, supplementation to mice with EGCG protected 
dopaminergic neurons in the substantia nigra pars compacta from toxicity induced MPTP, 
therefore it could preserve the levels of dopamine in the striatum (Levites et al., 2001). 
Similarly, the acute and chronic administration of EGCG has been evaluated in various cell 
and animal models of AD, where it has been suggested that EGCG significantly reduced the 
toxicity induced by ǃ-amyloid (Kelsey et al., 2010). With respect to PD, Sung et al, 2010, used 
models in vitro and in vivo to investigate the modulation of the effects of EGCG on L-dopa 
and induced neuronal damage. The results indicated that oral supplementation with this 
antioxidant initiated potential beneficial effects in patients with PD treated with L-dopa as 
moderately inhibits methylation of this molecule. Similarly, Levitas et al., 2001, using mice 
as animal model of PD which were given a pre-treatment with green tea extract (0.5 and 1 
mg / kg) or EGCG (2 and 10 mg / kg) prevented the damage generated by the neurotoxin 
(MPTP) on dopaminergic neurons in the nigrostriatal pathway. 
Another type of molecular mechanism involved in neuroprotection by EGCG is mediated 
gene activation in apoptosis. Evidence of this assertion is found in studies such as that by 
Levites et al., 2002, which results in neuroblastoma cells SH-SY5Y showed that EGCG 
decreased the gene expression of pro-apoptotic such as Bax, Bad, Fas ligand and TRAIL 
(tumor necrosis factor-related apoptosis-inducingligand), however, the expression of Bcl-2 
and Bcl-x was not affected (Levites et al., 2002). These results suggest that the 
neuroprotective effects of EGCG may involve the inactivation of proapoptotic genes, rather 
than the action of anti-apoptotic mitochondrial proteins (Ramassamy, 2006). Taken together, 
these findings indicate that EGCG may be a therapeutic candidate for chronic 
neurodegenerative diseases like AD and PD (Weinreb et al.,2004; Frank & Gupta, 2005), and 
may be beneficial in acute episodes of neuronal damage, such as spinal cord trauma. 
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4.4.1.2 Quercetin 
Quercetin is a flavonoid found in different types of food such as apples, capers, onions, 
broccoli, tea and wine (Boots et al., 2008; Esposito et al., 2002; Kelsey et al, 2010). As EGCG, 
quercetin has been widely studied in in vitro and in vivo assays in neural models (Ossola et 
al., 2009). Thus, PC12 cell studies showed that quercetin enhances cell survival in the 
presence of hydrogen peroxide (Dajas et al., 2003; Heo & Lee, 2004), linoleic acid (Sasaki, et 
al., 2003), and tert-butyl (Silva et al., 2008). Furthermore, in human neuroblastoma cells SH-
SY5Y used as experimental models for PD, this substance has shown to have protective 
ability against toxicity by 6-OHDA (Kelsey et al., 2010). Also, other study about 
neurodegeneration in animal models have suggested that the neuroprotective capacity of 
quercetin could be related to increased blood-brain barrier permeability, thus facilitating the 
penetration of the substance in the brain (Ossola et al., 2009).  
Taken together, these studies indicate that quercetin has the potential, such as EGCG, to 
block the starting of the enzymatic oxidation of dopamine (Tamura et al., 1994), and this 
could means a new therapy against neurodegenerative diseases such as PD (Kelsey et al., 
2010). However, Ossola, et al., 2009 states that despite the fact that quercetin has not shown 
significant toxicity in several animal studies, the risk of neurotoxicity is not negligible due to 
its narrow therapeutic dose range in in vitro experiments, also the effectiveness of quercetin 
in ND is quite low. 
4.4.1.3 Resveratrol  
Resveratrol (trans-3, 4 ',5-trihydroxystilbene) is a polyphenol found abundantly in grapes 
and red wine, it is known for its antioxidant and neuroprotective properties in several 
experiments, therefore, consumption of wine has been proposed as a possible benefit in 
neurodegenerative processes (Calabrese et al., 2010; Esposito et al., 2002; Kiziltepe et al., 
2004; Ramasamy, 2006). The main biological activities attributed to resveratrol include: 
inhibition of lipid peroxidation and free radicals in cell cultures and rat brains (Virgili & 
Contestabile, 2000, Casetta et al., 2005), vasodilator, anti-inflammatory and anticancer. Also, 
It has been shown that mice fed with daily dose of resveratrol for 45 days, had resveratrol or 
its metabolites in the brain, indicating its bioavailability to neuronal cells (Casseta et al., 
2005; Contestabile, 2001; Karuppagounder et al., 2008; Ramesh et al., 2010). 
In the field of ND has been suggested that resveratrol not only attenuated the cytotoxicity 
induced by ǃ-amyloid, but also blocks the accumulation of intracellular reactive oxygen 
species typical of apoptosis (Casetta et al., 2005; Jang & Surh, 2003). In addition, partial 
neuroprotection was demonstrated in rats with chronic supplementation of resveratrol in in 
vivo studies of excitotoxicity related to the administration of agonists for glutamate and 
kainic acid receptors,  (Contestabille, 2001; Virgili & Contestabile, 2000). The consumption of 
about 8 mg/kg/day of resveratrol for 45 days decreased excitotoxic damage measured on 
the basis of the reduction of certain neuromarcador of GABAergic neurons, from 38% to 14% 
in the olfactory cortex and 27 % to 12% in the hippocampus. This was the first report of 
neuroprotection by long-term administration of resveratrol in an in vivo model of 
neurodegeneration (Contestabille, 2001). Similarly, Han, 2003, showed that cell death 
induced by administration of ǃ-amyloid peptide (20μM), decreased significantly, and 
protein concentration-dependent by treatment with resveratrol administered 2 hours later. 
Also, in two different transfected cell lines (HEK293 and N2A), Marambaud et al., 2005, 
showed that resveratrol may reduce the secretion of ǃ-amyloid peptide, perhaps through 
the activation of proteosomal degradation of the peptide. This effect of resveratrol occurred 
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without the direct involvement of the ǃ and Ǆ-secretase, but, Brannon & Trygve, 2010, 
argues that resveratrol can activate transmembrane protein α-secretase. However, it is still 
unclear the effect of resveratrol on the mechanism of degradation of ß-amyloid levels in 
neurons, although it is suggested that may have a key effect on the route of clearance of 
beta-amyloid (Marambaud et al., 2005; Ramesh et al., 2010). 
With respect to cell signaling pathways related to the effects of resveratrol has been shown 
that its protective activity is related to the PCK phosphorylation, leading to its activation, 
and the activation of no amyloidogenic cleavage pathways of APP, decreasing the release of 
ǃ-amyloid (Han, 2003; Ramesh et al., 2010). Similarly, studies in neuroblastoma cells SH-
SY5Y by Miloso et al.,1999, argue that resveratrol can induce activation of MAP kinases 
ERK1 and ERK2. In addition to these signaling pathways, resveratrol can also induce the 
expression of the response of the transcription early growth factor (Egr1) (Della Ragione et 
al., 2002), which could regulate some aspects of synaptic plasticity related to learning and 
memory (Li et al., 2005). Additionally, resveratrol may interact with other proteins, 
including members of the sirtuins family. Deacetylases sirtuins are related to mechanisms of 
cellular longevity (Guarente, 2001), resveratrol acts as a potent activator of these molecules, 
thus related to neuroprotective pathways (Araki et al., 2004; Ramesh et al., 2010). Other 
intracellular signaling mechanisms that may be implicated with the neuroprotective effect of 
resveratrol against ǃ-amyloid peptide include the modulation of NF-kB pathways or NF-
κB/SIRT1, where resveratrol can inhibit the activity of NF-kB induced ǃ-amyloid peptide 
through the activation of SIRT1 (Ramassamy, 2006). 
With respect to the high amounts of resveratrol contained in red wine, investigations that 
assess moderate alcohol consumption show that this practice was significantly associated 
with lower risk of acquiring dementia and AD, compared to non-consumption (Casseta et 
al., 2005). Similarly, several epidemiological studies indicate that moderate wine 
consumption may be associated with a lower incidence of AD (Lindsay et al., 2002; 
Orgogozo et al., 1997; Truelsen et al., 2002), and additionally, different studies in vitro and in 
vivo have investigated the basis for this association. For example, doses from 10 microM of 
resveratrol in PC12 cells have demonstrated protective ability against the cytotoxicity 
induced by amyloid ǃ (Jang & Surh, 2003). It has also been reported that the combination of 
resveratrol with other flavonoids such as catechin, may exert synergistic protection against 
the toxicity of amyloid ǃ peptide in PC12 cells (Conte et al., 2003). However, there has not 
been demonstrated the relevance of these findings in vivo models (Ramassamy et al., 2010). 
Moreover, it is difficult to reconcile the therapeutic potential of resveratrol with the well 
known toxic effects of ethanol (Calabrese et al., 2010), because it does not seem reasonable to 
recommend alcohol consumption to those with tendency to addiction (Ramesh et al, 2010; 
Resnick & Junlapeeya, 2004). 
4.4.1.4 Ginkgo biloba 
The extract of Ginkgo biloba EGb 761 is a substance from the green leaves of Ginkgo biloba 
(Drieu, 1986). This extract was patented in 1990 and has a wide range of biochemical and 
pharmacological activities, including the antioxidant activity (Marcocci et al., 1994), the 
neurotrophic capacity in the hippocampal formation (Barkats et al., 1995; Bastianetto & 
Quirion, 2002), and the neuroprotective ability against neurotoxicity induced by β-amyloid 
peptide (Casseta, et al., 2005; Luo et al., 2002; Yao et al., 2001;).  
The therapeutic use of Ginkgo biloba has been proposed due to its high content of 
flavonoids and terpenoids, and is widely used in Europe to alleviate symptoms associated 
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with the progression of cognitive impairment, in fact, several studies argue that extracts of 
Ginkgo biloba may be effective in delaying the clinical deterioration of patients with 
dementia (Ernst & Pittler, 1999; Casseta et al., 2005). The effects of EGb 761 may be 
explained, at least in part, based on their protective actions in animal models of hypoxia and 
ischemia (Droy-Lefaix et al., 1995) and in vitro models of toxicity (Ni et al., 1996; Oyama et 
al., 1996; Xin et al., 2000), also a prospective placebo-controlled study demonstrated the 
therapeutic efficacy of oral administration of EGb 761 in dementia patients and healthy 
adults showed improved memory and attention (Bastianetto & Quirion, 2002; Maurer et al., 
1997; Mix et al., 2000). A case-control study that used a cohort of 1,462 women aged 75 years 
was conducted to test the effectiveness of the prevention of AD using EGb761, the 
conclusion is that the small number of women who developed dementia were prescribed 
with the supplement at least for two years. These results suggest that EGb 761 treatment 
may reduce the risk of developing Alzheimer's dementia in older women (Andrieu et al, 
2003; Casseta, et al., 2005).  
Additionally, Bastianetto & Quirion,  in 2002, conducted a study in vitro with embryonic 
mouse hippocampal cells on which were used two different protocols of citotoxididad, one 
with ǃ-amyloid (A_25-35 (25_M) A_1-40 (5_M) A_1-42 or (25_M)), and the other with 
sodium nitroprusside (SNP) to assess whether the components of red wine were able to 
reduce cell death caused by ǃ-amyloid and oxidative stress. We found that EGb 761, 
possibly through the antioxidant properties of its flavonoids was able to protect 
hippocampal cells against the toxic effects previously described.  
The mechanisms of action underlying the protective effects of EGb 761, have been evaluated 
in different studies. For example Bastianetto& Quirion, in 2002, noted in his study that the 
treatment with EGb 761 were able to inhibit the injury induced by ǃA 25-35, and NO. In 
addition, the extract showed protective effect against the harmful effects of H2O2, a 
supposed mediator of the toxicity caused by ǃ-amyloid (Behl et al., 1994). These data 
suggest that the scavenging properties of hydroxyl radical of the EGb 761, may be part of 
the protection against ǃ-amyloid toxicity (Oyama et al., 1996; Bastianetto & Quirion, 2002). 
Finally, it has been reported that EGb 761 inhibits a number of apoptotic events induced by 
ǃA 25-35, a process that may be relevant to the neuro-degeneration that occurs in AD 
(Johnson, 1994). In addition, these anti-apoptotic effects of EGb 761 are apparently related to 
the ability to inhibit the toxicity induced by H2O2, and that this natural extract has been 
reported as an effective tool to the apoptosis hydroxyl radical-induced in cultured neurons 
(Bastianetto & Quirion, 2002; Ni et al., 1996, Xin et al., 2000). 
4.4.1.5 Curcuminoides 
The curcuminoids are the active component of turmeric, which have been attributed to have 
capacity as an inhibitor of lipid peroxidation, and free radical scavenger, it is a potent anti-
inflammatory and anticancer, and is also traditionally used in Asia (Aggarwal et al., 2007; 
James, et al., 2009; Ramesh et al., 2010). In light of its antioxidant, anti-inflammatory and 
anti-amyloid actions, curcumin is being investigated as a candidate compound for the 
prevention or treatment of diseases such as multiple myeloma, pancreatic cancer, 
myelodysplastic syndromes, colon cancer, psoriasis and AD (Calabrese et al., 2010; Goel, et 
al., 2008). 
The curcumin reduces pro-inflammatory cytokines, oxidative damage, the Aǃ42 and 
cognitive deficits in models of AD (Frautschy et al., 2001). Also, has been told that it is a 
direct inhibitor of ǃA aggregation and fibril formation (Cole et al., 2003; James et al., 2009). 
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Similarly, curcumin has anti-AD activities, including, limitation of the kinase JNK (c-Jun N-
terminal protein kinase) and stimulation of neurogenesis (Cole et al., 2007; James et al., 
2009). Moreover, previous research has shown that turmeric reduces inflammation and 
oxidative damage in Tg2576 transgenic mouse brain AǃPPSw (Kumar & Singh, 2008; Lim et 
al., 2001,), and that curcumin reduces the level of soluble and insoluble ǃA in several brain 
regions. Therefore, it has been suggested that this substance could prevent the onset of AD, 
not only by scavenging reactive oxygen species, but also by inhibiting the aggregation of ǃA 
in the brain (Ramesh et al., 2010). Similarly, Lim et al., 2001, studied the effects of the 
curcumin in transgenic mice carrying a human mutation of the amyloid precursor protein 
(APPsw) that causes AD (Lim et al., 2001) and found a reduction in brain level of oxidized 
proteins, and a decrease in both the level of soluble and insoluble ǃA, and the plaque 
burden (Lim et al., 2001). However, more studies are needed to test the potential therapeutic 
use of curcumin for the treatment or prevention of AD in humans (Calabrese et al., 2010). 
The benefits of curcumin derive from its complex chemical structure and its ability to 
influence multiple signaling pathways, for instance, survival pathways such as those 
regulated by NF-kB, the Nrf2-dependent cytoprotective pathways, and routes of metastasis 
and angiogenesis (Calabrese et al., 2010; Goel et al.,2008; Ramsewak et al., 2000). 
Because curcumin is highly toxic and has a limited bioavailability, the assessment of their 
impact on clinical practice has not been easy, however, using lipid formulations, this 
obstacle has been largely mitigated (Begum et al., 2008; James et al., 2009; Calabrese et al., 
2010). 
5. Dietary recommendations for patients with ND as AD and PD  
Some evidence suggest that high intake of dietary antioxidants or fruits and vegetables 
provides nutritional compounds with antioxidant properties that may contribute to 
improving the quality of life, due to the decreased risk of degenerative diseases associated 
with aging and the accumulation of free radicals (Meydani et al.,1998). Therefore, although 
it is important to consider that dietary supplementation with AO may enhance cognitive 
longevity, and to some extent, reduces the risk of developing these diseases, it is also 
important to do some additional considerations. For example, the use of a single 
antioxidant, is not the best option, since the oxidation of individual antioxidants may 
promote oxidative stress, therefore, we recommend using combinations of antioxidants at 
the appropriate doses. Also, as mentioned previously, it has been found that diets rich in 
vitamin E may reduce the risk of EP, and has also been suggested that moderate wine 
consumption may reduce the risk to suffer from AD. However, there is still controversy 
about the epidemiological data related to these hypotheses, which could be due partially to 
the intrinsic difficulties of epidemiological surveys on the eating habits in large populations 
(Esposito, et al., 2002).  
However, nutritional factors remain a very relevant topic when setting up a comprehensive 
treatment in patients with dementia. In addition, the formulation of a specific diet for people 
with AD or PD, requires a prior careful review of the patient, in order to identify their 
nutritional deficiencies, and thus design a healthy diet to ensure good physical health. For 
example, certain vitamins such as B12 and folic acid must be replaced to ensure that AD 
dementia is not due in part to this deficiency (Ramesh et al, 2010). 
Finally, some authors argue that there is a lack of knowledge on these issues among medical 
professionals and clinicians, so they overlooked some dietary recommendations that could 
www.intechopen.com
 
Free Radicals, Neuronal Death and Neuroprotection 
 
187 
be used in conjunction with the approach of Neurogerontology (James et al, 2009), so, it is 
necessary to continue investigating the potential benefits of various AO against the 
prevention and/or treatment of ND as AD and PD. 
6. Conclusions 
As described earlier in this chapter, a variety of scientific evidence that describes the 
importance of different oxidative mechanisms which are part of the dynamic biological 
relevance of the ND as AD, PD or the CDS. Such approaches have led to a series of theories 
on the therapeutic use of antioxidants to slow down the chain reaction of oxidative events 
and thus to reduce its cytotoxic effects. Thus, consumption of antioxidants such as vitamin E 
and C, polyphenols and other antioxidants has became very important because they provide 
a series of defense mechanisms that promote longevity, reduce the risk of developing certain 
neuropathologies, and also can be consumed in a daily diet.  
However, there are some data that are incompatible with these theories, leading to various 
disputes regarding antioxidant supplementation and its possible beneficial effects on the 
body. In this sense, it is important to consider factors that may limit somewhat the research 
in this field. Among these factors: choosing an appropriate dose, long-term monitoring of a 
large cohort study, the inclusion or exclusion of different environmental factors, and in vivo 
application of the results obtained in in vitro studies. 
Occasionally, the start of antioxidant therapy for ND, is given when there may be a 
significant number of injured neurons, giving rise to specific clinical symptoms. In this case, 
antioxidants act on viable neurons, but do not recover the population of dead neurons. 
Therefore, in several studies of neuroprotection, supplying long-term supplements at the 
onset of the disease or even earlier is recommended; these results provide a valid evidence 
of the therapeutic effects of these substances and are a guarantee of further trials. 
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